Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Compugen (CGEN) has released an update. Compugen reported strong third-quarter financial results for 2024, with a net profit of $1.3 million, a ...

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At ...

Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.

Compugen Ltd. is a clinical-stage cancer immunotherapy company, pioneering computational target discovery to identify new drug targets and biological pathways ... largely due to milestone payments ...

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

By Bhanvi Satija and Puyaan Singh (Reuters) - The U.S. Food and Drug Administration on Tuesday declined full approval for ...

The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

All seemed set fair with magrolimab when Gilead reported a 91% overall response rate (ORR) with the drug in combination with azacitidine in previously-untreated MDS at ASCO in 2020, which earned ...

SACO – Kenneth G. “Greg” McGrovern passed away on Nov. 7, 2024. He was 94. Born on July 31, 1930, in Portland, Maine, Greg ...